

Qiuzhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3422824/publications.pdf>

Version: 2024-02-01

33
papers

906
citations

471509

17
h-index

501196

28
g-index

33
all docs

33
docs citations

33
times ranked

1650
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. <i>Scientific Reports</i> , 2014, 4, 5177.	3.3	93
2	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41339-41349.	1.8	79
3	Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. <i>Stem Cells</i> , 2015, 33, 354-366.	3.2	54
4	Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 598-607.	2.7	53
5	The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2016, 7, 626-632.	2.5	51
6	Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. <i>Oncotarget</i> , 2016, 7, 26670-26679.	1.8	51
7	IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. <i>Onc Immunology</i> , 2018, 7, e1373234.	4.6	47
8	Protein kinase CK2 α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 34800-34817.	1.8	46
9	Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. , 2021, 9, e001696.		42
10	Decreased expression of interleukin-36 α correlates with poor prognosis in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1675-1685.	4.2	35
11	Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 16248-16261.	1.8	28
12	Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 40920-40933.	1.8	27
13	Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. <i>Chinese Journal of Cancer</i> , 2017, 36, 77.	4.9	26
14	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26
15	Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2016, 55, 64-76.	2.7	24
16	<p>IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6691-6702.	1.9	24
17	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6457-6468.	1.9	23
18	A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9202.	3.3	22

#	ARTICLE	IF	CITATIONS
19	Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 6323-6334.	1.8	21
20	PD-L1 expression patterns in tumour cells and their association with CD8 ⁺ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. <i>Journal of Cancer</i> , 2019, 10, 1154-1161.	2.5	18
21	Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. <i>Oncolmmunology</i> , 2020, 9, 1752563.	4.6	15
22	Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. <i>Oncolmmunology</i> , 2015, 4, e1038017.	4.6	14
23	Dendritic cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 2499-2511.	2.7	14
24	CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 825-834.	4.2	14
25	Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. <i>Journal of Cancer</i> , 2018, 9, 3447-3455.	2.5	11
26	Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2020, 89, 107139.	3.8	11
27	A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. <i>Oncotarget</i> , 2015, 6, 27267-27274.	1.8	9
28	Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 209-215.	2.3	9
29	<i>TES</i> functions as a Mena-dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. <i>Cancer Communications</i> , 2019, 39, 1-14.	9.2	7
30	Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. <i>Journal of Cancer</i> , 2018, 9, 4204-4214.	2.5	4
31	OK432 synergizes with IFN γ to confer dendritic cells with enhanced antitumor immunity. <i>Immunology and Cell Biology</i> , 2014, 92, 263-274.	2.3	3
32	Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients. <i>Journal of Cancer</i> , 2017, 8, 606-616.	2.5	3
33	New nomograms to predict overall and cancer-specific survival of angiosarcoma. <i>Cancer Medicine</i> , 2021, 11, 74.	2.8	2